We are international
Donate
• treatment options TEXT SIZE   
Novel Therapies

Kyprolis, a next-generation proteasome inhibitor, received expanded FDA approval in January, 2016. It is now approved in combination with dexamethasone, or with Revlimid(R) (lenalidomide) + dexamethasone, for the treatment of patients with relapsed or refractory myeloma who have received 1 to 3 prior lines of therapy. It is also approved as a single agent for the treatment of relapsed or refractory myeloma patients who have had 1 or more lines of therapy.

General Information
Clinical Trials
Webcasts
Teleconferences
Blogs and Press Releases
Links
Kyprolis®; for Injection Tip Card
Onyx Pharmaceuticals 360™ (Onyx 360)
Onyx 360 is a comprehensive patient and caregiver support and services program designed to help patients navigate the treatment journey, including reimbursement and payment support, treatment support and referrals to third-party organizations for day-to-day and emotional support.

Understanding Kyprolis®; (carfilzomib) for Injection
This booklet discusses Kyprolis, the results of clinical trials with Kyprolis, how and when it is administered, its possible side effects, and how to manage them.